FIGURE 106. Random-effects meta-analysis – ADAS-cog at 12 weeks (mean change from baseline): donepezil (all dosages) vs placebo.

FIGURE 106Random-effects meta-analysis – ADAS-cog at 12 weeks (mean change from baseline): donepezil (all dosages) vs placebo

apooled 5 mg/day and 10 mg/day arms.

From: Appendix 5, Combined-dose and dose-specific meta-analyses

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.